NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs
NETTER-P: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
CLINICALTRIALS.GOV IDENTIFIER: NCT04711135
DRUG/TREATMENT: Lutetium [177Lu] oxodotreotide/dotatate
SPONSOR: Advanced Accelerator Applications (AAA)
Dr. Aman Chauhan Discusses "NETTER-P" Lutathera in Adolescent Patients
Advanced Accelerator Applications (AAA) is sponsoring a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.